123 results about "Scar tissues" patented technology

A detachable electrode and anchor utilized with electrode leads and leadless medical implants that enable explantation of the electrode while leaving the anchor in place. The detachable electrode and anchor utilizes a detachable mechanism that detachably couples the electrode to the anchor. Embodiments do not require removal of existing scar tissue before explantation, which minimize chances of internal bleeding at the extraction site. Embodiments also minimize impact on the vein in which the electrode lead travels by eliminating use of a necessarily larger diameter sheath that is utilized around the electrode lead to remove the electrode lead and attached anchor.

The invention is a non-surgical method for the eradication of pigmentation and scar tissue from an area of skin. The method comprises repeatedly puncturing the area of skin with an array of needles. As the needles are inserted into the skin, the needles and surface of the skin are washed with a clean solution. As the needles are withdrawn from the skin, the flow of clean solution ceases and the dirty solution, which contains cellular fluids and pigments released by the action of the needles, is removed from the surface. The invention is also a solution, which is used to clean the needles and to aid in destroying the pigment containing cells, and an apparatus, which is especially designed to move the needles into and out of the surface of the skin and to provide synchronization of the motion of the needles and flow of the solution such as to maximize the effectiveness of the method.

A method of treating glaucoma in an eye utilizing an implanted shunt having an elastomeric plate and a non-valved elastomeric drainage tube. The plate is positioned over a sclera of the eye with an outflow end of the elastomeric drainage tube open to an outer surface of the plate. An inflow end of the drainage tube tunnels through the sclera and cornea to the anterior chamber of the eye. The drainage tube collapses upon initial insertion within an incision in the selera and cornea, or at a kink on the outside of the incision, but has sufficient resiliency to restore its patency over time. The effect is a flow restrictor that regulates outflow from the eye until a scar tissue bleb forms around the plate of the slunt. The plate desirably has a peripheral ridge and a large number of fenestrations, and a longer suturing tab extending from one side of the plate to enhance visibility and accessibility when suturing the shunt to the selera.

A catheter assembly includes catheter having proximal and distal ends and at least one lumen extending between the ends. At least one end of the catheter is formed from a material that can be trimmed to achieve a selected length for the catheter. A tubular connector is telescoped over the catheter and a hub is joined to the tubular connector. Proximal portions of the hub are configured for connection to a medical apparatus. A cuff is mounted around the tubular connector or the catheter. The cuff is formed from a material that will permit or promote the growth of scar tissue for anchoring the catheter device at least on a semi-permanent basis in a patient.

A urethra support having an elongated mesh tape portion and a mesh extension affixed to the tape portion transverse thereto. In accordance with a method of the invention, the urethra support is inserted into the lower pelvic cavity of a patient with the tape portion forming a sling extending beneath and supporting the urethra of the patient. In this position, the tape portion is generally perpendicular to the urethra. The extension is inserted into the peri-urethral fascia along at least a portion of the length of the urethra. This induces the formation of scar tissue proximate the extension, with the scar tissue eventually contracting thereby compressing the urethra.

Systems, delivery devices, and methods to treat to ablate, damage, or otherwise affect tissue. The treatment systems are capable of delivering energy to nerve tissue in a target region such that at least a portion of the nerve tissue is replaced by scar tissue or otherwise altered to inhibit reinnervation in the target region.

A system simulates stimulation of scar tissue identified as hyper-enhanced areas in a medical image with variable luminance thresholds and categorizes partially-viable myocardium as distinct from non-viable scar tissue. A cardiac function analysis system includes a repository of imaging data representing a 3D volume comprising a patient heart. A model processor provides a model of the patient heart using the imaging data said model being for use in allocating electrical properties to model parameters determining electrical conductivity associated with image data classified as, (a) scar tissue, (b) impaired tissue and (c) normal heart tissue. The electrical properties allocated to scar tissue are different to electrical properties allocated to normal tissue. A stimulation processor simulates electrical stimulation of the patient heart using the model to identify risk of heart impairment.

A transitional mesh and thread for use in the human body is dissolved. The transitional mesh being comprised of sections of non-absorbable mesh fabric with sections of absorbable mesh fabric, such that each non-absorbable section is attached to absorbable mesh fabric. The non-absorbable mesh sections can be overlaid with absorbable mesh which after it is absorbed leaves the non-absorbable mesh in an array without connection to each other. The thread to be used to create the mesh has non-absorbable fibers that can be discontinuous, loosely woven or embedded in an absorbable material. The fabric mesh itself can be loosely woven and coated with absorbable material. The patterns of non-absorbable mesh and space between non-absorbable mesh sections can be varied to provide various strengths and degrees of motion and movement. The mesh can also be coated with materials to reduce infection, provide tissue growth, reduce scar tissue or other medicinal purposes.

An anchorage device comprising a mesh substrate coupled to an implantable medical device is disclosed, where the mesh substrate has a coating comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the mesh over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and / or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate.

The invention describes novel nitrosated and / or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and / or nitrosylated, and at least one nitric oxide donor compound and / or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and / or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and / or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

A therapeutic device includes a power unit for cyclically moving a therapeutic head unit at a frequency selected to cause compression wave energy to propagate through body tissue to a target scar tissue structure. The therapeutic head unit includes a plurality of differently shaped therapeutic heads to be pressed against the body surface.

A method of treating glaucoma in an eye utilizing an implanted shunt having an elastomeric plate and a non-valved elastomeric drainage tube. The plate is positioned over a sclera of the eye with an outflow end of the elastomeric drainage tube open to an outer surface of the plate. An inflow end of the drainage tube tunnels through the sclera and cornea to the anterior chamber of the eye. The drainage tube collapses upon initial insertion within an incision in the sclera and cornea, or at a kink on the outside of the incision, but has sufficient resiliency to restore its patency over time. The effect is a flow restrictor that regulates outflow from the eye until a scar tissue bleb forms around the plate of the shunt. The plate desirably has a peripheral ridge and a large number of fenestrations, and a longer suturing tab extending from one side of the plate to enhance visibility and accessibility when suturing the shunt to the sclera.

A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and / or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and / or salts thereof and / or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

The invention discloses scald and burn dressing prepared by a coaxial electrostatic spinning method. The scald and burn dressing is a nanofiber membrane with a core / shell structure, wherein the shell is made of a natural biological high molecular material and the core is a degradable synthetic high molecular material loaded with astragaloside. The mass ratio of astragaloside to the degradable synthetic high molecular material is 1:(2-50). The invention further discloses a preparation method of the scald and burn dressing. The raw materials are easy to get and cheap, and the preparation process is simple, easy to operate and control and can be easily put into large-scale industrial production. The prepared scald and burn dressing has good flexibility and high mechanical strength, and can form a protective fiber felt on the surface of the wound to promote growth of normal skin tissues and reduce formation of scar tissues, thereby curing skin injury.

The invention discloses a skin caring composition having a function of removing acne marks, a preparation and a preparation method of the skin caring composition. The skin caring composition consists of the following functional components in parts by weight: 0.01-2 parts of zinc carbonate hydroxide, 0.01-0.1 part of borax, 0.001-0.01 part of amber powder, 0.001-0.05 part of pearl powder, 0.05-0.5 part of allantoin, 1-5 parts of butyrospermum parkii, 0.1-0.5 part of angelica extract, 0.1-0.5 part of bighead atractylodes rhizome extract, 0.01-0.1 part of centella extract and 0.025-0.1 part of borneol. The skin caring composition is scientific and strict in formula, definite in effect and free from toxic and side effect, and is capable of effectively removing acne marks and other scar tissues; the skin caring composition has a function of removing acne marks, and is capable of obviously reducing skin roughness and content of skin melanin and the like; and the skin caring composition can guarantee a good skin status.

The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and / or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and / or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end-stage renal disease.

The present invention is directed to a method for combining assessment of different factors of dyssynchrony into a comprehensive, non-invasive toolbox for treating patients with a CRT therapy device. The toolbox provides high spatial resolution, enabling assessment of regional function, as well as enabling derivation of global metrics to improve patient response and selection for CRT therapy. The method allows for quantitative assessment and estimation of mechanical contraction patterns, tissue viability, and venous anatomy from CT scans combined with electrical activation patterns from Body Surface Potential Mapping (BSPM). This multi-modal method is therefore capable of integrating electrical, mechanical, and structural information about cardiac structure and function in order to guide lead placement of CRT therapy devices. The method generates regional electro-mechanical properties overlaid with cardiac venous distribution and scar tissue. The fusion algorithm for combining all of the data suggests cardiac segments and routes for implantation of epicardial pacing leads.

The invention describes novel nitrosated and / or nitrosylated rapamycin compounds, and novel compositions comprising at least one nitrosated and / or nitrosylated rapamycin compound, and, optionally, at least one nitric oxide donor compound. The invention also provides novel compositions comprising at least one rapamycin compound and at least one nitric oxide donor compound and / or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating and / or preventing cardiovascular diseases, for the prevention of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating and / or preventing pathological conditions resulting from abnormal cell proliferation; transplantation rejections; autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and / or therapeutic treatment of restenosis by administering nitrosated and / or nitrosylated rapamycin compounds or rapamycin compounds in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

The invention discloses an optoacoustic / ultrasonic dual mode endoscope based on piezoelectric micromachined ultrasonic transducer arrays. The optoacoustic / ultrasonic dual mode endoscope includes a piezoelectric micromachined ultrasonic transducer (PMUT) array probe (2), a PMUT array element (1), an integrated circuit (3), a plane lens (4), a condenser lens (6), an optical fiber coupling collimator (7), a single-mode fiber (8), an optical fiber FC / APC connector (9), an optical fiber (10), a signal line (11) and an housing (12). The optoacoustic / ultrasonic dual mode endoscope is characterized in that, the piezoelectric micromachined ultrasonic transducers are adopted, the transducers and the integrated circuit are good in compatibility during manufacturing process, and the transducers are easy to form an array; transducer arrays are adopted, the endoscope does not need to rotate, the imaging speed is raised, real time imaging is achieved; and the multiple transducer arrays can effectively raise the signal to noise ratio of a signal, deep imaging through focusing and scanning is achieved. The optoacousitc / ultrasonic dual mode endoscope can be widely applied to fields of medical endoscopes and industrial flaw detection, and particularly has great application value in in-vivo scar tissue identification, assessment of damage of ablation of tissue, atherosclerotic degree assessment and the like.

The invention provides a biodegradable cardia support. The biodegradable cardia support comprises a biodegradable support framework which is formed by weave of biodegradable high polymer material filaments, and a layer of controlled-release drug layer is coated on the surface of the biodegradable support framework. The support framework and drug carriers are made of high polymer biodegradable materials and can fully and automatically degradate after time window treatment is finished, and therefore the trouble of taking out the support is avoided. In addition, the controlled-release drug layer can release anti-inflammatory drugs stably through drug controlled-release technology, and therefore fibroblast hyperplasia caused by esophagus repair reaction can be effectively restrained, subsequent scar tissue hyperplasia and thickening can be reduced, and tissue hyperplasia on the surface of the support after the support is implanted is restrained. Thus, the time window of support implantation treatment can be prolonged, supporting force of the support on tube walls can be increased, and long-dated reappearance can be reduced.

An elastic structure is introduced percutaneously into the left ventricle and attached to the walls of the ventricle. Over time the structure bonds firmly to the walls via scar tissue formation. The structure helps the ventricle expand and fill with blood during the diastolic period while having little affect on systolic performance. The structure also strengthens the ventricular walls and limits the effects of congestive heart failure, as the maximum expansion of the support structure is limited by flexible or elastic members.

The present invention concerns a machine for martial arts training that simulates sparring with a live partner and provides a safe tool for body hardening. The machine is a vertical alignment of three independently rotatable alpha bodies having arms and a weighted base, where each alpha body rotates when met by force from a user or may rotate to initiate strikes via servomotors. The machine facilitates martial arts offensive strikes and defensive moves, which safely promotes the formation of calcium deposits and scar tissue about key nerve areas to give the body a hardened feel.

The invention discloses a Chinese medicinal composition for treating concrement, which is characterized in that: the Chinese medicinal composition is prepared from the following components: 5 to 20g of Chinese angelica, 5 to 20g of combined spicebush root, 5 to 20g of corydalis, 5 to 25 g of white paeony root, 5 to 25g of immature bitter orange, 5 to 20g of officinal magnolia bark, 5 to 25g of elecampane, 5 to 20g of nutgrass galingale rhizome, 5 to 20g of finger citron, 5 to 25g of common burreed rhizome, 5 to 25g of zedoary, 5 to 20g of rhubarb, 80 to 150g of longhairy antenoron herb, 5 to 20g of areca seed, 5 to 25g of turmeric root-tuber, 5 to 20g of Chinese thorowax root, 5 to 25g of Chicken's gizzard-membrane and 3 to 6g of liquoric root. The Chinese medicinal composition can effectively improve clinical symptoms to resolve tetany and relieve pain, maintains and improves gallbladder function, prevents and treats the concrement, and has the effects of coursing liver and disinhibiting gallbladder, abating jaundice, softening and loosening scar tissue, relieving inflammatory response and the like so as to promote the concrement to be moved, dissolved and discharged. The Chinese medicinal composition can effectively improve symptoms of uronephrosis, nephrcystosis, nephrauxe, renal deformation, nephrarctia and renal hypofunction, combines large, medium and small concrement, and has reliable cure rate.

A method for treating a scar on a skin surface of a subject is provided. A subject is identified as having a skin surface with scar tissue. In response to identifying the subject as having the scar tissue, a housing comprising at least one acoustic transducer is placed on the skin surface with the scar tissue and the acoustic transducer is activated to apply high intensity focused ultrasound energy to a portion of the scar tissue. Other embodiments are also described.

A method is provided for preventing or reducing the formation of adhesions or scar tissue either from the result of a surgical procedure or due to other irritation, trauma or other type of disruption of the tissue, by applying rapamycin or its derivatives or variants to a tissue.